Scholarlink

Background <p>Mongolia has a high prevalence of liver disease from chronic viral hepatitis infections, which can compromise the immune response. It is unclear whether people with chronic liver disease produce a robust antibody response to the COVID-19 vaccines. We investigated whether the antibody response to the COVID-19 booster vaccination differed between those with and without chronic viral hepatitis from multiple viral types.</p> Methods <p>Participants from Mongolia were recruited to the International Study on COVID-19 Vaccine to Assess Immunogenicity, Reactogenicity and Efficacy (InVITE). Demographic information was recorded and participants’ SARS-CoV2 anti-Spike antibody levels were measured at visit 1 (prior to administration of booster vaccine at baseline) and visit 2 (approximately 2 +/-1 months after booster vaccination). We used linear regression to determine if the anti-Spike antibody responses differed between participants with and without different types of chronic viral hepatitis infections.</p> Results <p>Overall, there was no significant difference in the anti-Spike antibody response between participants with and without chronic viral hepatitis, a result suggesting that COVID-19 vaccine booster immunogenicity is not affected by chronic hepatitis. Participants with chronic HCV infection produced a robust antibody response, but based on our linear regression analysis, this response seemed to wane faster than in participants without chronic viral hepatitis.</p> Conclusions <p>Our finding that there was no significant difference in the anti-Spike antibody response between participants with and without chronic viral hepatitis adds to the evidence that the COVID-19 vaccines are immunogenic in people with chronic viral hepatitis, including in those with HBV/HDV coinfection.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

COVID-19 vaccine immunogenicity in Mongolian adults with and without chronic hepatitis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月24日

查看全文
  • Viviane Callier,
  • Ganbolor Jargalsaikhan,
  • Munguntsetseg Batkhuu,
  • Renee Ridzon,
  • Sally Hunsberger,
  • Irini Sereti,
  • Kathryn Shaw-Saliba,
  • Shera Weyers,
  • Alyson Francis,
  • Naranjaral Dashdorj

摘要

Background

Mongolia has a high prevalence of liver disease from chronic viral hepatitis infections, which can compromise the immune response. It is unclear whether people with chronic liver disease produce a robust antibody response to the COVID-19 vaccines. We investigated whether the antibody response to the COVID-19 booster vaccination differed between those with and without chronic viral hepatitis from multiple viral types.

Methods

Participants from Mongolia were recruited to the International Study on COVID-19 Vaccine to Assess Immunogenicity, Reactogenicity and Efficacy (InVITE). Demographic information was recorded and participants’ SARS-CoV2 anti-Spike antibody levels were measured at visit 1 (prior to administration of booster vaccine at baseline) and visit 2 (approximately 2 +/-1 months after booster vaccination). We used linear regression to determine if the anti-Spike antibody responses differed between participants with and without different types of chronic viral hepatitis infections.

Results

Overall, there was no significant difference in the anti-Spike antibody response between participants with and without chronic viral hepatitis, a result suggesting that COVID-19 vaccine booster immunogenicity is not affected by chronic hepatitis. Participants with chronic HCV infection produced a robust antibody response, but based on our linear regression analysis, this response seemed to wane faster than in participants without chronic viral hepatitis.

Conclusions

Our finding that there was no significant difference in the anti-Spike antibody response between participants with and without chronic viral hepatitis adds to the evidence that the COVID-19 vaccines are immunogenic in people with chronic viral hepatitis, including in those with HBV/HDV coinfection.